Tuesday, July 30 1:00 p.m. - 1:20 p.m. Location: Exhibit Hall Theater #2 Sponsored by Omega Bio-Tek
Recent advancements and studies have demonstrated the potential of cfDNA as a universal, non-invasive biomarker in cancer prognosis, diagnosis, and management of prenatal testing. To harness the full potential of cfDNA, important considerations should be given to 1) preanalytical stabilization to minimize cfDNA degradation post-sample collection, 2) reliable cfDNA extraction methodology to maximize cfDNA yield with minimal genomic DNA contamination, and 3) appropriate downstream technology with high sensitivity to draw relevant conclusions. Here, we aim to equip researchers with a simple and efficient semi-automated cfDNA extraction workflow and present droplet digital PCR (ddPCR) as a powerful tool for detecting ultra-low variants with high specificity.
Kiran Durvasula Product Manager, Omega Bio-Tek
Be the first to get all the latest news.